zandelisib

After FDA setback, MEI, Kyowa confirm phase 2 efficacy with Japanese blood cancer data drop
Fierce Biotech
Fri, 11/18/22 - 10:45 am
Kyowa Kirin
MEI Pharma
zandelisib
clinical trials
non-Hodgkin lymphoma
FDA Concerns Over PI3K Inhibitors Snag MEI Pharma, Kyowa Kirin
BioSpace
Fri, 03/25/22 - 10:35 am
MEI Pharma
Kyowa Kirin
FDA
zandelisib
PI3k inhibitor
Mei, with Bayer and Gilead in its sights, posts pivotal data on blood cancer prospect
Fierce Biotech
Tue, 11/30/21 - 10:41 am
MEI Pharma
blood cancer
follicular lymphoma
zandelisib
Bayer
Gilead Sciences